Advertisement

Topics

US FDA grants orphan drug status to Ocugen's OCU300 to treat ocular graft versus host disease

08:23 EDT 10 Aug 2017 | PharmaBiz

Ocugen, a clinical stage biopharmaceutical company developing novel treatments for sight─threatening diseases, announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD)

Original Article: US FDA grants orphan drug status to Ocugen's OCU300 to treat ocular graft versus host disease

NEXT ARTICLE

More From BioPortfolio on "US FDA grants orphan drug status to Ocugen's OCU300 to treat ocular graft versus host disease"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...